Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm phase II study of KJ103 in anti-glomerular basement membrane disease
CTR20243543Phase 2Completed
- Sponsor
- Shanghai Baoji Pharmaceutical
- Start
- Sep 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ricefidase in anti-glomerular basement membrane disease, sponsored by Shanghai Baoji Pharmaceutical. Started Sep 2024; status: completed.
02
Drugs
ricefidase
03
Conditions
anti-glomerular basement membrane disease
Beyond the preview
Go deeper on CTR20243543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243543.